Clinical Trials Browser

Phase 2 × cabozantinib × Endocrine × Clear all

NCT05773274 2026-04-15

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

Phase 2 Recruiting

Metastatic Digestive System Neuroendocrine Tumor G1

NCT06900595 2026-04-14

Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer

Phase 2 Recruiting

Adrenocortical Carcinoma

NCT02867592 2026-04-13

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

Phase 2 Active not recruiting

109 enrolled 24 charts

CNSEndocrineGastrointestinalGenitourinarySarcoma

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Wilms Tumor, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Central Nervous System Neoplasms, Hepatoblastoma, Sarcoma, Clear Cell, Sarcoma, Alveolar Soft Part, Adrenocortical Carcinoma, Carcinoma, Medullary

NCT03914300 2026-04-13

Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer

Phase 2 Active not recruiting

11 enrolled 11 charts

EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

NCT04079712 2026-04-13

Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors

Phase 2 Active not recruiting

17 enrolled 12 charts

EndocrineNETThoracic

Carcinoma, Neuroendocrine, Neuroendocrine Tumors, Small Cell Lung Carcinoma

NCT04412629 2026-04-06

Cabozantinib in High Grade Neuroendocrine Neoplasms

Phase 2 Active not recruiting

High Grade Neuroendocrine Neoplasms

NCT06006013 2026-02-18

Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer

Phase 2 Recruiting

Adrenal Cortex Neoplasms, Adrenocortical Carcinoma

NCT05263050 2025-12-03

Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors

Phase 2 Recruiting

EndocrineGenitourinaryNET

Clear-cell metastatic renal cell carcinoma, Carcinoid Tumor, Carcinoma, Renal Cell, Neuroendocrine Tumors

NCT02302833 2025-07-31

Cabozantinib S-malate in Treating Patients With Metastatic Pheochromocytomas or Paragangliomas That Cannot Be Removed by Surgery

Phase 2 Completed

21 enrolled 7 charts

Paraganglioma, Pheochromocytoma

NCT04400474 2025-06-19

CABATEN

Phase 2 Completed

93 enrolled 17 charts

CNSEndocrineHead & NeckNET

Adenocarcinoma, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors, Thyroid Carcinoma, Anaplastic

NCT04197310 2025-01-31

Cabozantinib and Nivolumab for Carcinoid Tumors

Phase 2 Completed

19 enrolled 10 charts

Carcinoid Tumor, Neuroendocrine Tumors

NCT04524208 2024-08-13

CABONEN

Phase 2 Active not recruiting

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT04893785 2024-06-18

CABOTEM

Phase 2 Recruiting

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

NCT01466036 2024-03-05

Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

Phase 2 Completed

61 enrolled 9 charts

Carcinoid Tumor, Adenoma, Islet Cell, Neoplasm Metastasis

NCT02041260 2021-10-15

A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting

Phase 2 Unknown

EndocrineHead & Neck

Differentiated Thyroid Cancer (DTC)

NCT04427787 2021-09-05

LOLA

Phase 2 Unknown

Neuroendocrine Tumors

NCT03630120 2021-07-14

Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer

Phase 2 Terminated

6 enrolled 9 charts

EndocrineHead & Neck

Thyroid cancer, medullary, Thyroid Cancer, Papillary, Thyroid Diseases, Thyroid Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary